TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
  • April 14, 2020

BRIDGEWATER, NJ—Sanofi plans to create an API manufacturing company that would combine the pharmaceutical manufacturer’s six European API production sites located in Italy, Germany, France, Hungary, and the UK. The new API company will be the second largest in the world and is to be headquartered in France and have 3,100 employees.

In other news, the FDA approved Sanofi’s Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone to treat adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.